Clinical Trials
26 trialsNCT06096844 2026-06-03
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
National Cancer Institute (NCI)
Phase 3 Recruiting
NCT04310007 2026-05-29
Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT06731907 2026-05-26
MK-3475-01G
Merck Sharp & Dohme LLC
Phase 2 Recruiting
NCT06704724 2026-05-22
A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.
Pfizer
Phase 1 Terminated
NCT05624996 2026-05-04
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
NRG Oncology
Phase 3 Recruiting
NCT05358548 2026-04-30
ATATcH Alternating Treatment Plans for Advanced Cancer
Rutgers, The State University of New Jersey
Phase 2 Recruiting
NCT06447662 2026-04-20
A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.
Pfizer
Phase 1 Recruiting
NCT03678883 2026-04-03
9-ING-41 in Patients With Advanced Cancers
Actuate Therapeutics Inc.
Phase 2 Active not recruiting
NCT04892953 2026-02-19
Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT03177291 2025-12-05
Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT05501665 2024-10-17
Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer
Vanderbilt-Ingram Cancer Center
Phase 1/2 Recruiting
NCT02250326 2024-09-19
abound2L+
Celgene
Phase 2 Completed
NCT04336098 2024-06-04
Study of SRF617 in Patients With Advanced Solid Tumors
Coherus Oncology, Inc.
Phase 1 Completed
NCT03345810 2023-06-15
DURATION
AIO-Studien-gGmbH
Phase 2 Completed
NCT02328105 2022-08-09
LCI-LUN-ABR-001: Carbo With Nab-Paclitaxel in Patients With Advanced NSCL Cancer
Wake Forest University Health Sciences
Phase 2 Completed
NCT00533949 2022-06-21
High-Dose or Standard-Dose Radiation Therapy and Chemotherapy With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery
Radiation Therapy Oncology Group
Phase 3 Completed
NCT00979212 2022-06-15
Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
Radiation Therapy Oncology Group
Phase 2 Completed
NCT02733250 2021-02-16
URCOH-PMS-001
Centre hospitalier de l'Université de Montréal (CHUM)
Phase 1/2 Completed
NCT02525653 2021-01-12
Albumin-Bound Paclitaxel and Gemcitabine in Patients With Untreated Stage IV or Recurrent Squamous Cell Lung Cancers
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT02027428 2020-08-17
Safety and Efficacy Study of Abraxane as Maintenance Treatment After Abraxane Plus Carboplatin in 1st Line Stage IIIB / IV Squamous Cell Non-small Cell Lung Cancer
Celgene
Phase 3 Completed
NCT02309177 2019-05-31
Safety Study of Nivolumab With Nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, Nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or Nab-Paclitaxel in Recurrent Metastatic Breast Cancer
Celgene
Phase 1 Completed
NCT02151149 2018-09-24
ABOUND 70+
Celgene
Phase 4 Completed
NCT00470548 2018-01-10
Abraxane and Alimta in Advanced Solid Tumors
University of California, Davis
Phase 1/2 Terminated
NCT00454324 2017-07-11
NRR
UNC Lineberger Comprehensive Cancer Center
Phase 2 Terminated
NCT00313599 2014-07-02
Lapatinib and Paclitaxel in Treating Patients With Advanced Solid Tumors
University of California, San Francisco
Phase 1 Completed
NCT00544648 2014-06-09
Ph I/II Nab-Paclitaxel & Carboplatin w/Concurrent Radiation Therapy for Unresectable Stg III NSCLC
Vanderbilt-Ingram Cancer Center
Phase 1/2 Terminated